Last updated: February 24, 2026
What is NDC 50742-0317?
NDC 50742-0317 corresponds to Blinatumomab (Blincyto), a bispecific T-cell engager approved for the treatment of certain types of acute lymphoblastic leukemia (ALL). It is administered in settings of relapsed or refractory disease, primarily for adults, and in some cases children.
Current Market Landscape
Market Size and Trends
The global leukemia therapeutics market was valued at approximately USD 3.5 billion in 2022 and is projected to reach USD 6.2 billion by 2028. Blincyto accounts for a significant segment of this market due to the rising incidence of ALL, especially in young adults and pediatric populations.
Incidence and Prevalence
- Approximate annual new cases of ALL in the U.S.: 6,000 (all ages).
- Relapsed or refractory cases account for about 30-40% of patients diagnosed.
- Pediatric ALL constitutes roughly 20% of new cases, with adult cases making up the majority.
Competitive Landscape
Key competitors and alternatives include:
- Inotuzumab ozogamicin (Besponsa)
- CAR-T therapies (Kymriah, Tecartus)
- Conventional chemotherapy regimens
The emergence of CAR-T therapies has altered the treatment landscape, but Blincyto retains a niche due to its distinct mechanism and approved indications.
Price Analysis
Current Pricing
- List price per cycle (28 days): Approximately USD 178,000 (as of 2023).
- Average treatment duration: 2-4 cycles, depending on patient response.
- Annual treatment costs: Range from USD 356,000 to USD 712,000.
Reimbursement and Payer Dynamics
- Patients typically rely on Medicare, Medicaid, or private insurance.
- Payers emphasize cost-effectiveness; pharmaceutical rebates and discounts influence net prices.
- The high cost is partially offset by the drug's targeted nature and potential to achieve remission in refractory cases.
Price Projections (Next 3-5 Years)
| Year |
Estimated List Price per Cycle |
Justification |
| 2023 |
USD 178,000 |
Current price, no major policy shifts |
| 2024 |
USD 180,000 |
Slight inflation adjustment |
| 2025 |
USD 182,000 |
Inflation, patent exclusivity effects |
| 2026 |
USD 180,000 - USD 185,000 |
Potential manufacturer negotiations |
| 2027 |
USD 183,000 - USD 188,000 |
Market competition intensifies |
Challenges like biosimilar entry and alternative therapies could suppress price growth. Yet, no biosimilar is currently in late-stage development that directly challenges Blincyto.
Price Drivers
- Patent protection until 2026-2028.
- Adoption rates driven by clinical trial data and reimbursements.
- Market entry of competition therapies.
- Use restrictions in specific indications.
Regulatory and reimbursement outlook
Reimbursement trends favor innovative therapies, especially for refractory conditions with limited options. CMS and private payers balance cost with clinical value, influencing net prices through negotiations.
Key Market Risks
- Patent expiry may lead to biosimilar competition, pressuring prices.
- Eventually, shifts toward alternative treatments may reduce market share.
- Price controls or policy reforms could impact profitability.
Summary
While the current list price for NDC 50742-0317 (Blincyto) remains around USD 178,000 per cycle, projections suggest stability with minimal growth in the short term. Long-term price trajectories depend on market competition, regulatory actions, and clinical demand.
Key Takeaways
- Blincyto's market remains stable with high treatment costs.
- Price projections are modest, subject to biosimilar entry and policy changes.
- The drug's niche positioning and lack of direct biosimilar competition presently sustain its pricing.
- Market growth aligns with the increasing incidence of ALL and refractory cases.
- Payer negotiations and potential policy reforms will influence net pricing dynamics.
FAQs
1. How does Blincyto compare price-wise with similar treatments?
Blincyto’s list price per cycle is roughly comparable to inotuzumab ozogamicin but higher than traditional chemotherapy regimens, reflecting its targeted mechanism and therapeutic niche.
2. What factors could reduce Blincyto’s price in the future?
Introduction of biosimilars, intensified payer negotiations, regulatory restrictions, and competition from CAR-T therapies could reduce prices.
3. How does the treatment duration influence overall costs?
Treatment typically requires 2-4 cycles, resulting in total costs ranging from USD 356,000 to USD 712,000 per patient annually.
4. Are there policies impacting drug pricing for oncology biologics?
Yes. Policies targeting biosimilar adoption, value-based pricing, and Medicare/Medicaid negotiations influence pricing strategies.
5. What market segments are most likely to adopt Blincyto?
Hospitals, specialty clinics, and academic centers treating refractory ALL patients, especially in the U.S. and Europe.
Sources
- MarketsandMarkets. (2022). Leukemia therapeutics market forecast.
- IQVIA. (2023). U.S. drug pricing and reimbursement report.
- FDA. (2014). Approval of Blincyto for ALL.
- Medscape. (2023). Oncology drug pricing analysis.
- GlobalData. (2022). CAR-T and antibody therapies competitive landscape.
